Abirateron
Classification: BATC code: L02BX03
Summary
As the substance is only used by men, analyses on sex or gender differences have not been considered relevant.
Additional information
Abiraterone is an inhibitor of 17 alpha-hydroxylase/C17,20-lyase (CYP17) that blocks androgen biosynthesis [1]. The approved indication for abiraterone in combination with methylprednisolone or prednisone is treatment of certain types of prostate cancer [2].
Updated: 2018-12-17
Date of litterature search: 2018-12-06
Reviewed by: Karin Schenck-Gustafsson
Approved by: Karin Schenck-Gustafsson